(VIANEWS) - Limestone Bancorp (LMST), Supernus Pharmaceuticals (SUPN), Gartner (IT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Limestone Bancorp (LMST)
15.5% sales growth and 12.29% return on equity
Limestone Bancorp, Inc. is the bank holding organization for Limestone Bank, Inc., which offers a variety of personal and commercial banking products. It offers deposit products such as savings, interest-checking, money market accounts and fixed rate certificates of varying maturities. The company also offers commercial loans to finance equipment, working capital and other business needs. It also offers commercial real estate loans, which include loans on borrowers' properties and tenants. Construction and development loans are secured by homes or commercial buildings, land in development, and home loans. The company also offers consumer loans and residential real estate loans. It also provides loans for agriculture, livestock and crops. Other loans include loans to municipalities and loans that are secured by stocks, overdrafts, or loans that are secured by stock. It also offers drive-through banking services and automatic teller machines. It serves small- to medium-sized communities, owners of such businesses and their employees, as well as other professionals and executives. There are 20 branches in Kentucky. The firm was previously known as Porter Bancorp, Inc., but it changed its name in May 2018 to Limestone Bancorp, Inc. Limestone Bancorp, Inc. is located in Louisville, Kentucky. It was established in 1902.
Limestone Bancorp's sales growth this year is expected to be 8.2% and 5.3% for next year.
Year-on-year quarterly revenue growth grew by 3.3%, now sitting on 52.34M for the twelve trailing months.
Volume
Today's last reported volume for Limestone Bancorp is 117 which is 96.69% below its average volume of 3535.
Limestone Bancorp's sales growth for the next quarter is 15.5%. The company's growth estimates for the present quarter and the next is a negative 12.3% and 13.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.29%.
Limestone Bancorp's Stock Yearly Top and Bottom Value
Limestone Bancorp's stock is valued at $20.34 at 20:22 EST, way under its 52-week high of $23.70 and way above its 52-week low of $17.23.
Limestone Bancorp's Moving Average
Limestone Bancorp's worth is above its 50-day moving average of $19.21 and above its 200-day moving average of $19.61.2. Supernus Pharmaceuticals (SUPN)
13% sales growth and 7.07% return on equity
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm that focuses on developing and marketing products to treat central nervous system disorders in the United States. TrokendiXR is an extended-release topiramate product that can be used to treat epilepsy and prophylaxis for migraine headaches. OxtellarXR is an extended-release oxcarbazepine to monotherapy partial onset epilepsy in children and adults aged 6-17 years. APOKYN is a drug that treats hypomobility and off episodes in advanced Parkinson's Disease patients. XADAGO is an adjunctive therapy to levodopa/carbidopa for patients experiencing off episodes. MYOBLOC is a type B toxin indicated to treat cervical dystonia in adults. SPN-812 is a product candidate that has been approved for use in the treatment and prevention of attention deficit hyperactivity disorder. SPN-830 is a drug/device combination candidate at late stage for the prevention or off episodes of PD. SPN-817 was a new product candidate in Phase I trials to treat severe epilepsy. SPN-820 was a product candidate in Phase I trials for treating treatment-resistant depression. It sells products via distributors and specialty pharmacies. The company has a partnership agreement with Navitor Pharmaceuticals, Inc. for a phase II clinical trial of NV-5138 in the treatment of depressive disorder. Rockville, Maryland is the headquarters of this company. It was established in 2005.
Supernus Pharmaceuticals's sales growth this year is anticipated to be 16.5% and a negative 10.1% for next year.
Year-on-year quarterly revenue growth grew by 20.3%, now sitting on 630.07M for the twelve trailing months.
Volume
Today's last reported volume for Supernus Pharmaceuticals is 192727 which is 46.67% below its average volume of 361453.
Supernus Pharmaceuticals's sales growth for the next quarter is 13%. The company's growth estimates for the ongoing quarter and the next is a negative 0% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.07%.
Volatility
Supernus Pharmaceuticals's last day, last week, and last month's current intraday variation average was 1.89%, 1.49%, and 1.77%, respectively.
Supernus Pharmaceuticals's highest amplitude of average volatility was 3.45% (day), 3.23% (last week), and 3.68% (last month), respectively.
Supernus Pharmaceuticals's Stock Yearly Top and Bottom Value
Supernus Pharmaceuticals's stock is valued at $34.39 at 20:22 EST, below its 52-week high of $36.08 and way above its 52-week low of $24.95.
Supernus Pharmaceuticals's Moving Average
Supernus Pharmaceuticals's value is above its 50-day moving average of $31.58 and way higher than its 200-day moving average of $30.28.3. Gartner (IT)
8.8% sales growth and 102.59% return on equity
Gartner, Inc. is a research- and advisory firm in the United States, Canada, Europe, Middle East, Africa, Europe, Canada, Europe, Middle East, Africa, as well as internationally. The company operates in three main segments, namely Research, Conferences, or Consulting. Its research is delivered primarily via a subscription service. This includes on-demand access data, benchmarks and published content as well access to research experts. Business professionals can learn, share and network at the Conferences segment. The Consulting segment provides market research and custom analysis as well as on-the ground support services. The segment offers solutions to IT-related issues, such as IT cost optimization and digital transformation. Gartner, Inc., was established in 1979. It is located in Stamford, Connecticut.
Gartner's sales growth this year is anticipated to be 12.9% and 13.5% for next year.
Year-on-year quarterly revenue growth grew by 16.3%, now sitting on 4.54B for the twelve trailing months.
Volume
Today's last reported volume for Gartner is 282427 which is 35.81% below its average volume of 440038.
Gartner's sales growth for the next quarter is 8.8%. The company's growth estimates for the current quarter and the next is 71.4% and 25.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 102.59%.
Volatility
Gartner's last day, last week, and last month's current intraday variation average was 0.91%, 1.50%, and 1.43%, respectively.
Gartner's highest amplitude of average volatility was 2.83% (day), 2.86% (last week), and 2.46% (last month), respectively.
Gartner's Stock Yearly Top and Bottom Value
Gartner's stock is valued at $287.63 at 20:22 EST, way under its 52-week high of $368.99 and way higher than its 52-week low of $149.74.
Gartner's Moving Average
Gartner's value is way under its 50-day moving average of $320.86 and above its 200-day moving average of $264.92.4. SunCoke Energy (SXC)
7% sales growth and 16.28% return on equity
SunCoke Energy, Inc. is an independent coke producer in Brazil and the Americas. It operates in three areas: Domestic Coke and Brazil Coke. Logistics is its core business. The company offers thermal and metallurgical coal. It also offers handling and/or mixed services for steel, coke and electric utility customers. It also owns and manages five cokemaking plants in the United States, and one in Brazil. SunCoke Energy, Inc., was established in 1960. It is located in Lisle, Illinois.
SunCoke Energy's sales growth this year is expected to be 18% and a negative 19.4% for next year.
Year-on-year quarterly revenue growth grew by 37.8%, now sitting on 1.67B for the twelve trailing months.
Volume
Today's last reported volume for SunCoke Energy is 660311 which is 13.37% below its average volume of 762264.
SunCoke Energy's sales growth is a negative 0% for the present quarter and 7% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 0% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.28%.
Volatility
SunCoke Energy's last day, last week, and last month's current intraday variation average was 1.12%, 0.87%, and 1.89%, respectively.
SunCoke Energy's highest amplitude of average volatility was 2.24% (day), 2.61% (last week), and 3.15% (last month), respectively.
SunCoke Energy's Stock Yearly Top and Bottom Value
SunCoke Energy's stock is valued at $7.14 at 20:22 EST, way below its 52-week high of $9.82 and way higher than its 52-week low of $5.85.